Lancet partner to develop and commercialize new medicines in Russia ChemRar High Tech Center.

ChemRar, Lancet partner to develop and commercialize new medicines in Russia ChemRar High Tech Center , the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Firm, have announced collaboration for research, development and commercialization of fresh medicines in Russia with the intention to stimulate the innovative advancement of the Russian pharmaceutical industry. Through the partnership ChemRar and Lancet plan to develop and manufacture new drugs in major therapeutic areas which certainly are a high priority for the Russian Federation health care system according to the significant Government strategy PHARMA-2020.This technique reveals details of the structure of brain tissue. Their evaluation revealed that the reduced useful connection they detected in brain areas of the older topics was correlated with decreased white matter integrity.?.

Boehringer Ingelheim improvements U.S. Ischaemic strokes take into account up to 92 percent of strokes suffered by individuals with atrial fibrillation, resulting in serious debilitation and poor frequently prognosis, stated Hans-Christoph Diener, M.D., Ph.D., Professor and Chairman, Section of Neurology, University Duisburg-Essen, Germany. For sufferers with atrial fibrillation, reducing the chance of stroke, especially ischaemic stroke, may be the main aim of anticoagulation treatment.